Blood donation may improve diabetes and fatty liver, study finds
NCT ID NCT03696797
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether regularly removing blood (like donating blood) can lower iron levels and improve diabetes control and fatty liver disease. 132 adults aged 40-75 with prediabetes or diabetes took part. The treatment group gave blood several times, while the control group did not. Researchers measured blood sugar, liver enzymes, and insulin function over 6 to 12 months.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- blood donation (phlebotomy)
- What this could lead to
- If it works, this could offer a simple, low-cost way to improve blood sugar control and liver health in people with diabetes and fatty liver disease.
- What could go wrong
- This is a completed trial with 132 participants, so results are limited. The intervention (blood donation) may not be effective for everyone, and risks include anemia or dehydration from blood draws.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
132 people
The number who actually took part.
- Started
-
May 2019
- Finished
-
Jan 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
40 to 75 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Ages 40-75 * At least 3 months since diagnosis of prediabetes or diabetes * HgbA1C value within three months or at screening of 5.7-6.4% for those with prediabetes and 7- 8.5% for those with diabetes (the upper limit of the latter to reduce the likelihood of major changes in glycemic intervention during the trial period, and the lower limit to allow some room for improvement) * Undiagnosed on no medication HgA1C 6.5-6.9 * C-reactive protein levels up to 11.0 * Aim 2-serum ALT\> 1.5 times the upper limit of normal, or; liver stiffness of \> 12.5 kPa by Fibroscan transient elastography * Serum ferritin levels within 1 year or at the time of screening in the upper half of the normal range (\>50 ng/mL for women; \>100ng/mL for men) Exclusion Criteria: * Documented anemia * Hemoglobin levels within 0.5 g/dL of the lower limit of normal (\<12.5 g/dL for women; 13.5 g/dL for men) * Recent blood loss * Bleeding diatheses (coagulation abnormalities or treatment with anticoagulants) * Serious chronic infections or chronic inflammatory conditions that could elevate ferritin as an "acute phase reactant * C-reactive protein greater than the upper limit of normal to further validate the lack of significant chronic inflammation * Active cancer diagnosis (excluding skin cell cancers other than melanoma) * Renal insufficiency (eGFR\<60 ml/min) * History of orthostatic hypotension * Heavy alcohol use (NIH criteria for men, greater than 4 drinks on any day or 14/week) * Pregnancy or premenopausal women of childbearing age, unless unable to become pregnant because of oral contraceptive use or surgical loss of ovaries or uterus * Aim 2 - individuals meeting the additional inclusion criteria for aim 2 will be tested for anti-HAV IgM, HBs Ag, anti-HBc. IgM, anti HCV IgM and IgG. Subjects who prove positive for any of these viral serologies, except for HCV IgG will be excluded. The latter will be tested for HCV RNA by PRC, and if negative they will be eligible for enrollment
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Diabetes are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of North Carolina at Chapel Hill (UNC)
Chapel Hill, North Carolina, 27599-2100, United States
-
Wake Forest University Health Sciences
Winston-Salem, North Carolina, 27157, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can four minutes of hard exercise match a longer workout for blood sugar?
- New pill takes aim at blood sugar in diabetes
- Home c-peptide tests could reveal hidden insulin production in diabetes
- Can a Plant-Based diet program help patients lose weight and improve heart health?
- Can a health coach in your patient portal help you lose weight?
- Brain scans may predict who is most at risk for dangerous low blood sugar